Piper Sandler analyst David Westenberg reiterated a Buy rating on Cytek Biosciences (CTKB – Research Report) today and set a price target of $15.00. The company’s shares closed yesterday at $8.92.
According to TipRanks, Westenberg is a 2-star analyst with an average return of 1.0% and a 44.14% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Guardant Health, Zoetis, and Natera.
Currently, the analyst consensus on Cytek Biosciences is a Moderate Buy with an average price target of $13.33.
See the top stocks recommended by analysts >>
The company has a one-year high of $16.05 and a one-year low of $6.45. Currently, Cytek Biosciences has an average volume of 986.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
Read More on CTKB:
